EU pediatrics rules are top regulatory headache for drug companies; variations and fees close behind
This article was originally published in SRA
The pediatric medicines legislation is the area in the EU drug regulatory system that companies are most concerned about and believe are of "high-priority" for improvement1.
You may also be interested in...
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.